177 related articles for article (PubMed ID: 19814673)
1. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
[TBL] [Abstract][Full Text] [Related]
2. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
3. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
4. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
5. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
6. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
Kontoghiorghes GJ; Kolnagou A; Peng CT; Shah SV; Aessopos A
Expert Opin Drug Saf; 2010 Mar; 9(2):201-6. PubMed ID: 20059374
[TBL] [Abstract][Full Text] [Related]
7. The 18th ICOC Proceedings in Athens, Greece: New breakthrough in thalassemia leading to the complete treatment of iron overload and to hundreds of patients achieving and maintaining normal body iron stores. Ethical questions on chelation therapy.
Kontoghiorghes GJ
Hemoglobin; 2010 Jun; 34(3):199-203. PubMed ID: 20524809
[TBL] [Abstract][Full Text] [Related]
8. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Kontoghiorghes GJ; Spyrou A; Kolnagou A
Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
[TBL] [Abstract][Full Text] [Related]
9. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
Porter JB; Davis BA
Best Pract Res Clin Haematol; 2002 Jun; 15(2):329-68. PubMed ID: 12401311
[TBL] [Abstract][Full Text] [Related]
10. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
Taher A; Hershko C; Cappellini MD
Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
[TBL] [Abstract][Full Text] [Related]
11. The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.
Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):181-5. PubMed ID: 21599430
[TBL] [Abstract][Full Text] [Related]
12. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
13. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A
Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684
[TBL] [Abstract][Full Text] [Related]
14. Iron Chelation for Iron Overload in Thalassemia.
Crisponi G; Nurchi VM; Lachowicz JI
Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855104
[TBL] [Abstract][Full Text] [Related]
15. Proceedings of the 17th International Conference on Chelation (ICOC) for the Treatment of Thalassemia, Cancer and Other Diseases Related to Metal and Free Radical Imbalance and Toxicity. November 2007. Shenzhen, China.
Hemoglobin; 2009; 33(5):283-397. PubMed ID: 20052787
[No Abstract] [Full Text] [Related]
16. Oral iron chelators.
Kwiatkowski JL
Hematol Oncol Clin North Am; 2010 Feb; 24(1):229-48. PubMed ID: 20113905
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
[No Abstract] [Full Text] [Related]
18. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
19. Role of T2* magnetic resonance in monitoring iron chelation therapy.
Carpenter JP; Pennell DJ
Acta Haematol; 2009; 122(2-3):146-54. PubMed ID: 19907152
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for thalassemia patients with osteoporosis.
Terpos E; Voskaridou E
Ann N Y Acad Sci; 2010 Aug; 1202():237-43. PubMed ID: 20712799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
